Read our companion blog post with visuals on this episode

This comprehensive analysis examines the impact of GLP-1 receptor agonists on health, particularly their significant efficacy in weight loss and treatment of diabetes. It highlights studies demonstrating the superior performance of newer dual-agonist medications like Zepbound compared to Wegovy, while also outlining the common gastrointestinal side effects and less frequent but more serious adverse events. Beyond metabolic improvements, the sources explore the expanding therapeutic benefits of GLP-1s, including cardiovascular protection, reduction in addiction behaviors, and positive effects on sleep apnea, kidney function, and even neurological health. Finally, the analysis discusses the rapid adoption of these medications in the U.S. amidst a national obesity and diabetes crisis, noting the high financial burden and existing disparities in access.

We have a companion blog post on this topic you can read here.

In this episode we discuss the growing childhood obesity crisis in the United States, highlighting its significant prevalence, health implications, and economic burden. It explores the complex causes, including dietary habits, lack of physical activity, socioeconomic factors, and psychological influences. 

We discuss traditional treatment approaches, emphasizing the importance of nutritional changes, increased physical activity, and behavioral support. Finally, it introduces and analyzes the role of GLP-1 medications like Wegovy and Zepbound as potential treatment options for adolescents, weighing their effectiveness, potential side effects, cost, and the need for comprehensive care.

Read our companion blog post on this episode

This episode discusses the phenomenon of sagging skin and facial changes, dubbed "Ozempic Face," that can occur after significant and often rapid weight loss, particularly when using GLP-1 medications like Ozempic, Wegovy and Zepbound.

We explain that this issue is caused by fast fat loss and the natural decline of skin elasticity proteins, compounded by factors like age and genetics. The article notes the commonality of these effects and presents various treatment options, ranging from surgical procedures to non-surgical methods like fillers and energy treatments, along with lifestyle adjustments to support skin health. Finally, it touches upon the emotional impact of these physical changes and the growing trend of integrated clinics offering combined weight loss and aesthetic care.

This episode explains how smart scales go beyond simply measuring total body weight by using Bioelectrical Impedance Analysis (BIA) to estimate various body composition metrics. These metrics, such as body fat percentage, visceral fat, muscle mass, bone mass, body water, protein percentage, Basal Metabolic Rate (BMR), metabolic age, and Fat-Free Body Weight, provide a more comprehensive view of health than weight alone.

We emphasizes that tracking trends in these metrics over time, supported by consistent measurements and companion apps, offers more insightful and motivating feedback for individuals pursuing health goals, although it notes that BIA is not as precise as clinical methods and readings can be influenced by factors like hydration. Ultimately, utilizing these detailed metrics can empower users to make informed lifestyle decisions and focus on overall health gain rather than just weight loss.

We recommend two different digital scales - one at a lower price point and one at a higher price point with more comprehensive features.  https://glp1tribe.com/store

You can read our companion blog post on this topic here 

Read the companion blog post to this episode with all the details.

In this episode we discuss the often-overlooked psychological impacts of using GLP-1 medications like Ozempic and Wegovy, highlighting that these treatments involve more than just physical changes. They explain the significant "mental load" patients experience, including the profound shift when "food noise" quiets, which can be both liberating and disorienting. 

We discuss and explore the complexities of body image as the body changes rapidly, noting issues like loose skin and "phantom fat," and address the potential for emotional fluctuations like anxiety or changes in mood. Finally, they emphasize the importance of seeking support, developing new coping strategies, and adopting a holistic approach to health that integrates both physical and mental well-being on this treatment journey.

Find more support at GLP1 Tribe

Read our companion blog post on this topic.

This episode provides a guide to maintaining weight loss after using GLP-1 medications. We emphasize that while these medications are effective tools, sustained success requires a multifaceted approach. Key strategies highlighted include continuing medication at a maintenance dose under medical supervision, adopting a sustainable diet focused on whole foods, protein, and fiber, engaging in regular physical activity including strength training, and prioritizing holistic well-being through adequate sleep, stress management, and attention to mental health. We stress that weight maintenance is an ongoing process and should involve collaboration with a healthcare team.

Visit GLP1 Tribe for more info and resources to help with your health journey.

Why Reducing Visceral Fat with GLP-1s is a Game Changer for Metabolic Health
Read our comprehensive blog post on this topic.

The presence of excess visceral fat, often "hidden" deep within the abdomen, poses a significant and often underestimated threat to long-term health. It is far more than an issue of weight; it is an active contributor to serious conditions such as type 2 diabetes, heart disease, liver disease, and potentially even dementia. Understanding its dangers is the first step towards taking proactive measures.

GLP-1 medications have emerged as a promising therapeutic option, offering a new approach not only for weight management but also for specifically targeting this harmful visceral fat and improving overall metabolic health. Their benefits can extend to better blood sugar control, improved cardiovascular risk factors, and potential protection for organs like the kidneys.

However, these medications are most effective when they are part of a comprehensive strategy that includes a commitment to sustainable lifestyle changes. Balanced nutrition, regular physical activity (with a strong emphasis on strength training to preserve muscle mass), adequate sleep, and stress management are crucial partners to GLP-1 therapy. This holistic approach ensures that individuals are not just losing weight but are building a foundation for lasting health.

The journey to better metabolic health is a personal one, and it begins with informed discussion. Individuals concerned about visceral fat or interested in learning more about GLP-1 medications are encouraged to use the information presented here to have productive conversations with their healthcare providers. By understanding their individual risks and the available options, and by actively participating in their care, individuals can take charge of their metabolic health and move towards a healthier future.

Follow GLP-1 news and trends on the GLP1Tribe.com web site. 

GLP-1 medications were cited as a main example today when Trump signed an executive order saying people in the US should pay the same price to pharma companies as what people in other countries pay for the same medications. I have to agree with the main point in that there hasn't been a great explanation for patients about why people in the US have to pay 5 times as much as people in other countries for the exact same medication.

The order, experts say, is a reimagined and far more aggressive version of Trump’s policy during his first term to cut drug costs, which failed to take effect after a federal judge blocked it.

The administration hasn’t singled out a specific class of drugs for price cuts, but officials said it’s fair to expect that GLP-1s — a class of drugs that includes Ozempic, Wegovy and Zepbound — will be included among them. 

The executive order signed today will kick off a round of negotiations with pharma companies who will likely push back on this saying they need to cover their R&D costs.

But I think it is great that the spotlight has been put on this issue.

The central issue is a stark difference in pricing structures. US list prices for these GLP-1 medications are exceptionally high, typically ranging from approximately $935 to $1,349 per month.These figures stand in sharp contrast to prices observed in comparable international markets, where the same medications often cost four to five times less, or even lower in some instances.For example, the US list price for Ozempic ($936) is reported to be over five times higher than in Japan ($169), and the US list price for Wegovy ($1,349) is nearly four times higher than in Germany ($328). 

While various patient assistance programs, manufacturer savings cards, and direct-purchase options exist in the US, significantly reducing out-of-pocket costs for certain patient segments – potentially down to $25 per month for some commercially insured individuals or around $499 per month for self-pay vial purchases – these mechanisms do not alter the fundamental high price structure that burdens the overall US healthcare system.This creates a complex landscape of access, where affordability varies dramatically depending on insurance status, income, and program eligibility.  

Novo Nordisk (maker of Ozempic and Wegovy) and Eli Lilly (maker of Mounjaro and Zepbound) dominate this multi-billion dollar market. Their pricing strategies appear tailored to exploit the unique dynamics of the US market, characterized by a lack of centralized government price negotiation power compared to peer nations.Other contributing factors to the high US prices include complex patent strategies employed by manufacturers to potentially extend market exclusivity and a pharmaceutical business model increasingly focused on maximizing shareholder returns. 

Ultimately, the substantial price differential for these highly effective medications raises critical questions regarding patient access, health equity, and the sustainability of healthcare spending in the United States compared to its international counterparts.

We personally wonder if GLP-1s were 80% less expensive if 20 million more people might take them and if people would take them for longer. If so, the pharma companies would ultimately likely make a lot more money and millions more people would benefit.

Read our comprehensive guide to getting insurance coverage and winning insurance appeals. 

We created this episode because getting insurance coverage and winning denial appeals can be overwhelming, frustrating, and confusing.  Wegovy and Zepbound can costs thousands of dollars a year if you don't get coverage so the stakes are high in getting this coverage many patients. 

Key Takeaways:

• Wegovy and Zepbound offer significant clinical benefits, including substantial weight loss and, for specific patient populations, reduction in cardiovascular risk (Wegovy) or improvement in obstructive sleep apnea (Zepbound). These additional FDA-approved indications can be pivotal for securing coverage, especially under plans like Medicare that restrict coverage for drugs solely for weight loss.
  
  
• The insurance approval process, particularly prior authorization, is a standard hurdle. Being thoroughly prepared with detailed medical documentation, a comprehensive history of previous weight loss attempts (including diet, exercise, and prior medications), and strong support from a healthcare provider are crucial for a successful PA submission.
  
  
• Insurance denials are common but not necessarily the final answer. Patients have the right to appeal these decisions, first through internal appeals with the insurer and then, if necessary, through an independent external medical review. Persistence, coupled with a well-documented case addressing the specific reasons for denial, can often lead to an overturned decision. Appeal success rates are significant enough to make the effort worthwhile.
  
  
• Manufacturer savings programs can substantially reduce out-of-pocket costs for commercially insured patients, both those with and without direct coverage for the medications. However, these programs have limitations, often exclude government beneficiaries, and may not make the drugs affordable for everyone.
  
  
• If coverage for Wegovy or Zepbound cannot be obtained, alternative FDA-approved weight management medications, comprehensive lifestyle interventions (diet, exercise, behavioral support), and, for appropriate candidates, bariatric surgery remain important and effective options to discuss with a healthcare provider. The field of obesity treatment continues to evolve, with new therapies in clinical trials offering future hope.

Getting enough fiber is a key to getting good results on a weight loss journey. 

In this episode we emphasizes that fiber is an essential nutrient when taking GLP-1 medications like Wegovy, Zepbound, Ozempic, or Mounjaro, going beyond simply managing side effects. It explains that fiber is the indigestible part of plants that benefits digestion, helping to counteract potential constipation caused by these medications and even aiding in blood sugar control and heart health.

This episode discusses the two types of fiber, soluble and insoluble, and provides guidance on gradually increasing intake while staying hydrated, suggesting the Bristol Stool Chart as a tool to monitor effectiveness. Finally, it offers practical tips for incorporating fiber into meals and notes situations where fiber intake might need temporary adjustment.

Read our companion blog post on this podcast episode about Fiber